Moderate-to-Severe Atopic Dermatitis: Separating Fact From Myth in Primary Care
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Click Here to Manage Email Alerts
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
Activity Description
Atopic dermatitis (AD) is a prevalent, chronic, inflammatory skin condition, affecting approximately 25% of children and 10% of adults. Persons with moderate-to-severe AD often experience a high disease burden that has a significant impact on quality of life. Recent years have seen a substantial expansion in the therapeutic armamentarium for moderate-to-severe disease, presenting both new opportunities and challenges for clinicians. Ongoing education is critical in increasing awareness of AD’s burden, guiding the appropriate use of novel therapies, and promoting best practices for interprofessional and multidisciplinary management. This text-based educational activity employs an interactive Facts and Myths format, challenging learners to distinguish between factual, evidence-based science and common misconceptions related to AD. Designed for a broad audience of US-based healthcare professionals, this engaging program specifically aims to dispel myths and reinforce facts about disease burden, therapeutic targets, evidence-based treatment, and interprofessional strategies to enhance patient outcomes.
Target Audience
The intended audience for this activity is US-based primary care physicians, internists, physician associates, nurse practitioners, and other healthcare professionals involved in the management of patients with atopic dermatitis (AD).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Address facts and myths on the impact and pathophysiology of moderate-to-severe AD.
- Address facts and myths on the mechanism(s) of action, efficacy, and safety of targeted systemic therapies for the treatment of moderate-to-severe AD.
- Address facts and myths on interprofessional team member roles that ameliorate outcomes for patients with moderate-to-severe AD.
Faculty
Sarah L. Chamlin, MD
Division of Dermatology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Professor of Pediatrics and Dermatology
Medical Director, Vascular Lesion Clinic
Northwestern University Feinberg School of Medicine
Chicago, IL
John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Jefferson Abington Health
Abington, PA
Medical Writer
Valerie Zimmerman, PhD
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Linda A. Giarraputo, BS, PA-C
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participants who opt-in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity.
Vindico Medical Education has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until June 13, 2025. PAs should only claim credit commensurate with the extent of their participation.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.
This enduring material is approved for 1 year from the date of original release, June 14, 2024 to June 13, 2025.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate or AAPA Category 1 CME credit certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Sarah L. Chamlin, MD
Speaker Contracted by Ineligible Company: Regeneron, Sanofi
John J. Russell, MD, FAAFP
Advisor: Pfizer, Sanofi
Consultant: Pfizer, Sanofi
Speaker Contracted by Ineligible Company: Pfizer, Sanofi
Medical Writer Reports the following relevant financial relationship(s)
Valerie Zimmerman, PhD No relevant financial relationships to disclose.
Reviewers report the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2024 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Procedures for Reporting Copyright Infringement
If you suspect that any content in this activity violates your copyright, you can request the removal of such content or restrict access to it by contacting our designated copyright agent (as outlined below). In your email, kindly provide the following details:
- Specify the copyrighted work you believe has been infringed upon.
- Describe the work and, if possible, include the location (eg, URL) of an authorized version of the work.
- Share your name, address, telephone number, and, if available, your email address.
- Assert that you genuinely believe that the use of the materials in question is not authorized by the copyright owner, its agent, or the law.
- Confirm that the information you have provided is accurate and send an attestation, "under penalty of perjury," that you are either the copyright owner or have the authority to act on behalf of the copyright owner.
- Provide a signature or its electronic equivalent from the copyright holder or a representative authorized to act on their behalf.
Our agent for copyright issues relating to this web activity is as follows:
Vindico Medical Education, LLC
Attn: Faith Bantivoglio
6900 Grove Road, Building 300
Thorofare, NJ 08086
fbantivoglio@vindicocme.com
or call: 856-994-9400, ext. 614
CE Questions?
Contact us at cme@vindicoCME.com